Actively Recruiting
Evaluating ALKS 2680 Tablets for Adults With Narcolepsy Type 2 in a Randomized, Placebo-Controlled Study
Led by Alkermes, Inc. · Updated on 2026-10-07
176
Participants Needed
44
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of ALKS 2680 tablets on reducing daytime sleepiness and symptoms in adults diagnosed with Narcolepsy Type 2 NT2. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of three different doses of ALKS 2680 compared with placebo tablets. The study is sponsored by Alkermes, Inc. and uses a parallel design to compare outcomes. Participants are randomly assigned to receive one of three dose levels of ALKS 2680 tablets or a placebo, taken orally once daily for 12 weeks. The study includes a triple-blind approach to ensure unbiased results. The primary focus is on measuring changes in mean sleep latency using the Maintenance of Wakefulness Test MWT from baseline through Week 12. Secondary outcome measures include assessments of sleepiness, cognitive complaints, fatigue, and global impression scales. Throughout the 12-week treatment, participants will undergo various evaluations such as the Epworth Sleepiness Scale, Patient Global Impression-Severity scale, and Psychomotor Vigilance Task, among others. Safety is monitored by recording treatment emergent adverse events up to 14 weeks. This study includes adults aged 18 to 70 years with a confirmed diagnosis of NT2. Overall participation spans just over 12 weeks, with regular assessments to track symptom changes and treatment effects.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Research Team
D
Director Clinical Trial Manager
D
Director Clinical Trial Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here